ASH 2018 | PD-1 & PDL-1 combinations with CAR T-cell therapy
David Maloney
• 15 Jan 2019
David Maloney, MD, PhD, of the Fred Hutchinson Cancer Research Center, Seattle, WA., discusses the safety and efficacy regarding the combination of various agents with CAR T-cell therapy, notably checkpoint inhibitors for PD-1 and PDL-1, which offer a bright future for those who relapse after CAR T-cell therapy, though it is still early days. This interview was recorded at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.
